US2008090803A1PendingUtilityA1

Fatty alcohol drug conjugates

53
Assignee: LUITPOLD PHARM INCPriority: Mar 23, 2001Filed: Aug 8, 2007Published: Apr 17, 2008
Est. expiryMar 23, 2021(expired)· nominal 20-yr term from priority
Inventors:Charles S. SwindellGlenn Fegley
A61P 43/00A61P 7/00A61P 9/00A61P 3/10A61P 9/10A61P 3/06A61P 25/18A61P 25/28A61P 25/00A61P 31/12A61P 35/02A61P 31/00A61P 35/00A61P 15/00A61P 13/00C07D 405/04C07D 473/16A61P 15/18A61P 15/08C07D 305/14C07D 519/04C07F 9/65616A61P 21/00A61P 17/16A61P 1/16A61P 1/00A61P 1/18A61P 17/06C07D 487/14C07D 401/04C07D 403/04A61P 1/12
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides conjugates of fatty alcohols and pharmaceutical agents useful in treating cancer, viruses, psychiatric disorders. Compositions, pharmaceutical preparations, and methods of preparation of the fatty alcohols-pharmaceutical agent conjugates are provided.

Claims

exact text as granted — not AI-modified
1 . A compound of the formula:  
       
         
           
           
               
               
           
         
         wherein R is a C 8 -C 26  fatty group of a fatty alcohol ROH and X is an anticancer drug moiety of an anticancer drug XOH, wherein the anticancer drug is not paclitaxel.  
       
     
     
         2 . The compound of  claim 1 , wherein the fatty alcohol ROH has a carbon structure that is the same as a carbon structure of a fatty acid occurring naturally in humans.  
     
     
         3 . The compound of  claim 1 , wherein the fatty alcohol ROH has a carbon structure that is the same as a carbon structure of a C 12 -C 26  fatty acid occurring naturally in humans.  
     
     
         4 . The compound of  claim 1 , wherein the fatty alcohol ROH has a carbon structure that is the same as a carbon structure of a C 14 -C 24  fatty acid occurring naturally in humans.  
     
     
         5 . The compound of  claim 1 , wherein the fatty alcohol ROH has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.  
     
     
         6 . A pharmaceutical preparation comprising a compound of the formula:  
       
         
           
           
               
               
           
         
         wherein R is a C 8 -C 26  fatty group of a fatty alcohol ROH, and X is an anticancer drug moiety of an anticancer drug XOH, and a pharmaceutically acceptable carrier, wherein the anticancer drug is not paclitaxel.  
       
     
     
         7 . The pharmaceutical preparation of  claim 6 , wherein the fatty alcohol ROH has a carbon structure that is the same as a carbon structure of a fatty acid from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.  
     
     
         8 . A method of making a compound of the formula:  
       
         
           
           
               
               
           
         
         comprising reacting an intermediate of the formula ROC(O)T with an anticancer drug of the formula XOH for a time sufficient to form the compound wherein R is a C 8 -C 26  fatty group of a fatty alcohol ROH, and X an anticancer drug moiety of anticancer drug of the formula XOH, wherein the anticancer drug is not paclitaxel.  
       
     
     
         9 . The method of  claim 8 , wherein the fatty alcohol ROH has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.  
     
     
         10 . A method of treating a disorder comprising administering to a subject in need of such treatment a pharmaceutical preparation comprising a compound of the formula:  
       
         
           
           
               
               
           
         
         and a pharmaceutically acceptable carrier wherein R is a C 8 -C 26  fatty group of a fatty alcohol ROH, and X is an anticancer drug moiety of an anticancer drug XOH.  
       
     
     
         11 . The method of  claim 10 , wherein the fatty alcohol ROH has a carbon structure that is the same as a carbon structure of a fatty acid selected from myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatetraenoic acid, docosapentaenoic acid, docosahexaenoic acid, and nervonic acid.  
     
     
         12 . The method of  claim 11  wherein the disorder is a mammalian cell proliferation disorder.  
     
     
         13 . The pharmaceutical preparation of  claim 6 , wherein the fatty alcohol ROH has a carbon structure that is the same as a carbon structure of a fatty acid occurring naturally in humans.  
     
     
         14 . The pharmaceutical preparation of  claim 6 , wherein the fatty alcohol ROH has a carbon structure that is the same as a carbon structure of a C 12 -C 26  fatty acid occurring naturally in humans.  
     
     
         15 . The pharmaceutical preparation of  claim 6 , wherein the fatty alcohol ROH has a carbon structure that is the same as a carbon structure of a C 14 -C 24  fatty acid occurring naturally in humans.  
     
     
         16 . The method of  claim 8 , wherein the fatty alcohol ROH has a carbon structure that is the same as a carbon structure of a fatty acid occurring naturally in humans.  
     
     
         17 . The method of  claim 8 , wherein the fatty alcohol ROH has a carbon structure that is the same as a carbon structure of a C 12 -C 26  fatty acid occurring naturally in humans.  
     
     
         18 . The method of  claim 8 , wherein the fatty alcohol ROH has a carbon structure that is the same as a carbon structure of a C 14 -C 24  fatty acid occurring naturally in humans.  
     
     
         19 . The method of  claim 10 , wherein the fatty alcohol ROH has a carbon structure that is the same as a carbon structure of a fatty acid occurring naturally in humans.  
     
     
         20 . The method of  claim 10 , wherein the fatty alcohol ROH has a carbon structure that is the same as a carbon structure of a C 12 -C 26  fatty acid occurring naturally in humans.  
     
     
         21 . The method of  claim 10 , wherein the fatty alcohol ROH has a carbon structure that is the same as a carbon structure of a C 14 -C 24  fatty acid occurring naturally in humans.

Join the waitlist — get patent alerts

Track US2008090803A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.